Non-FTE Costs. All other costs and research requirements associated with the Discovery Program that are not within the scope of the Discovery Plan shall be borne by Loxo, including the costs of GLP toxicology studies. If the JRC specifically requests, as confirmed by Loxo in writing or in the written Discovery Plan approved by the JRC, that Array conduct and fund a research activity at an external center, Array’s out-of-pocket external costs incurred by Array in following such request shall be reimbursed at Array’s cost. Loxo shall reimburse all non-FTE costs incurred by Array withing thirty (30) days after receipt of an invoice therefor.
Non-FTE Costs. If the JRC specifically requests, as confirmed by GSK in writing or in the written Research Plan approved by the JRC, that CK conduct and fund a research activity at an external center, CK's out-of-pocket external costs incurred by CK in following such request shall be reimbursed at CK's cost; provided that, if CK identifies that a particular task can be efficiently performed by a Third Party, CK may satisfy its FTE commitment with personnel from such Third Party if such Third Party is approved by the JRC, and that, unless the JRC determines otherwise, such Third Party personnel will be deemed a CK FTE for purposes of the Research Plan and this Agreement.
Non-FTE Costs. If any Development Plan (other than the Impetigo Plan for Impetigo POC) includes, and NovaBay conducts and funds any activity using Third Party resources or acquires any capital equipment, Galderma shall reimburse NovaBay for the actual amounts paid by NovaBay for such Third Party activities or capital equipment (provided such equipment will be transferred to Galderma at the end of the Agreement Term) subject to production of receipts or other evidence of payment, all as approved by Galderma in the Development Plans. ***Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
Non-FTE Costs. If the Discovery Research Plan or Development Plan includes, and NovaCal agrees, that NovaCal conduct and fund any activity using Third Party resources or acquire any capital equipment, Alcon shall reimburse NovaCal for the actual amounts paid by NovaCal for such Third Party activities or capital equipment subject to production of receipts or other evidence of payment, all as pre-approved by Alcon.
Non-FTE Costs. Non-FTE costs and research requirements associated with performance of the Research Collaboration at Array shall be borne by Array, except that Array shall not be required to incur any extraordinary [ * ] costs without Array’s prior written consent. Extraordinary [ * ] costs means material costs in excess of [ * ].
Non-FTE Costs. It is understood that the R&D Costs will include out-of-pocket costs incurred by Introgen for items other than FTEs, including without limitation amounts paid to consultants or for sponsored research or the like. In addition, R&D Costs may include costs for equipment and facilities acquired for purposes of the R&D Program; provided that if such equipment or facilities are used both (i) in the course of performing the R&D Program and (ii) for other purposes by Introgen, then the costs of such equipment or facilities shall be allocated between the R&D Program and such other purposes in accordance with generally accepted accounting principles. It is understood that if Introgen acquires any capital equipment or facilities in connection with the R&D Program, whether or not separately identified in the Development Plan and Budget, Introgen shall own all such capital equipment and facilities, unless the parties otherwise agree. [*] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Non-FTE Costs. If the JRC specifically requests, as confirmed by AZ in writing or in the written Research Plan approved by the JRC, that Array conduct and fund a research activity at an external center, Array’s [ * ] costs incurred by Array in following such request shall be reimbursed by AZ at Array’s cost [ * ]. Such sums shall be payable [ * ] following receipt by AZ of a valid invoice from Array.
Non-FTE Costs. Non-FTE costs and research requirements associated with performance of the Research Collaboration at Array shall be borne by Array, except that (a) Array shall not be required to incur any extraordinary [ * ] costs without Array’s prior written consent, (b) Array may bxxx InterMune for materials used in the course of manufacture and analytic activities and of process research at a rate of [ * ] and (c) Array may bxxx InterMune no more frequently than once per calendar quarter for reasonable costs incurred by Array in connection with the permitted outsourcing of activities by Array as provided in the Research Plan at a rate of [ * ]. Extraordinary chemical or screening costs means material costs in excess of [ * ]. InterMune shall pay any invoices received pursuant to Section 5.1.3(b) within [ * ] of receipt.”
Non-FTE Costs. Takeda shall reimburse Array for the actual cost of chemicals, chemical reagents and related materials necessary or useful for conduct of the Research Program, where such materials cost more than [***] total per one order, provided, however, that Array obtains Takeda's approval prior to incurring any such expense. Array shall submit invoices for such materials on a monthly basis, and Takeda shall pay each such invoice within [***] days of receipt thereof. In addition, Takeda shall reimburse any out-of-pocket expenses incurred by Array in connection with the Research Program; provided, however, that Array obtains Takeda's approval prior to incurring any such expense.
Non-FTE Costs. It is understood that the Development Costs will include reasonable costs for items other than FTEs, including without limitation amounts paid to consultants, third party clinical trial sites or the like. In addition, Development Costs may include costs for equipment and facilities acquired for purposes of the Development Program or production of Collaboration Products; provided that if such equipment or facilities are used both (i) in the course of -------------------- * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portion.
